Amgen (AMGN) has seen significant share price gains over multiple years. Despite these gains, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 42.2%, with an estimated intrinsic value of $647.81 per share compared to its recent price of $374.75. The article also presents “Narratives” for investors, offering bull and bear case valuations based on differing assumptions about future growth, product pipelines, and market risks.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Is Amgen (AMGN) Still Attractively Priced After Strong Multi Year Share Price Gains
Amgen (AMGN) has seen significant share price gains over multiple years. Despite these gains, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 42.2%, with an estimated intrinsic value of $647.81 per share compared to its recent price of $374.75. The article also presents “Narratives” for investors, offering bull and bear case valuations based on differing assumptions about future growth, product pipelines, and market risks.